Shares of CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) dropped 4.3% during trading on Monday . The stock traded as low as $2.55 and last traded at $2.69. Approximately 17,866 shares changed hands during trading, a decline of 96% from the average daily volume of 462,595 shares. The stock had previously closed at $2.81.
CytoMed Therapeutics Price Performance
The business has a 50 day moving average price of $2.69 and a two-hundred day moving average price of $2.19.
CytoMed Therapeutics Company Profile
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Featured Articles
- Five stocks we like better than CytoMed Therapeutics
- Stock Dividend Cuts Happen Are You Ready?
- Merck: 4 No-Brainer Reasons to Buy This Dip
- What is the Australian Securities Exchange (ASX)
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- 3 Tickers Leading a Meme Stock Revival
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
